Guerbet: Guerbet Strengthens Its Executive Committee With Two New Appointments to Accelerate Its Commercial and Industrial Development
Guerbet: Guerbet Strengthens Its Executive Committee With Two New Appointments to Accelerate Its Commercial and Industrial Development
Raoul Bernhardt - Director of Industrial OperationsGuerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development
Guerbet通過兩項新任命加強其執行委員會，以加快其商業和工業發展
- Dan Raffi appointed Director of Commercial Operations
- Raoul Bernhardt appointed Director of Industrial Operations
- 丹·拉菲被任命為董事商業運營主管
- 拉烏爾·伯恩哈特被任命為工業運營的董事
Villepinte, 10 July 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments. Dan Raffi and Raoul Bernhardt have joined the Group as Director of Commercial Operations and Director of Industrial Operations respectively. They will both become members of Guerbet's Executive Committee
維爾品特，2023年7月10日：Guerbet(FR0000032526 GBT)是一家全球醫學成像造影劑和解決方案專家，該公司宣佈通過兩項任命來加強其管理團隊。丹·拉菲和拉烏爾·伯恩哈特已分別以商業運營董事和工業運營董事的身分加入該集團。他們都將成為格爾貝特執行委員會的成員
Dan RAFFI - Director of Commercial Operations
丹·拉菲--董事商業運營
Raoul Bernhardt - Director of Industrial Operations
拉烏爾·伯恩哈特--工業運營的董事
Guerbet's Executive Committee now has 9 members:
格爾貝執行委員會現在有9名成員：
- David Hale, Chief Executive Officer
- Charlotte Bamière, Director of Legal Affairs
- Raoul Bernhardt, Director of Industrial Operations
- Philippe Bourrinet, Director of Development, Medical & Regulatory Affairs, and Group Chief Pharmacist
- Valérie Brissart, Director of Diagnostic Imaging
- Jérôme Estampes, Chief Financial Officer and Senior VP Business Development and Licensing
- Leïla Mechaï, Director of Human Resources and Corporate Social Responsibility
- François Nicolas, Director of R&D, R&I and Chief Digital Officer
- Dan Raffi, Director of Commercial Operations
- 首席執行官David·黑爾
- 夏洛特·巴米·̀Re，董事法律事務
- 拉烏爾·伯恩哈特，董事工業運營
- 菲利普·布爾裡內，董事發展、醫療和監管事務主管，集團首席藥劑師
- 診斷成像的淡水河谷́Rie Brissart，董事
- JÉrôMe Estanpe，首席財務官兼業務開發和許可高級副總裁
- 人力資源與企業社會責任董事總監Leïla Mechaï
- 研發、R&I公司董事研發總監兼首席數位官Frçois Nicolas
- 丹·拉菲，董事商業運營
Upcoming events:
即將舉行的活動：
Publication of first-half annual revenue
20 July 2023 after trading
公佈上半年年度收入
2023年7月20日盤後
About Guerbet
關於格爾貝
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a world leader in medical imaging, offering a complete range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. Pioneers in contrast media for 95 years, with more than 2,830 employees worldwide, we are constantly innovating and devote 8% to 10% of our revenue to research and development in five centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022. For more information, please visit .
在格爾貝，我們建立持久的關係，讓人們生活得更好。這就是我們的目標。我們是醫療成像領域的世界領先者，提供全套藥品、醫療設備以及用於診斷和介入成像的數位和人工智慧解決方案。我們作為對比媒體的先驅已有95年的歷史，在全球擁有超過2,830名員工，我們不斷創新，並將8%至10%的收入投入法國、以色列和美國的五個中心的研發。Guerbet(GBT)在巴黎泛歐交易所(B-中型股)上市，2022年創造了7.53億歐元的收入。欲瞭解更多資訊，請訪問。
Attachment
依附
- 2023 07 10 - GUERBET - Appointments in Executive Committee
- 2023 07 10-Guerbet-執行委員會成員任命
